Literature DB >> 29305640

Stem cell therapy in early post-traumatic talus osteonecrosis.

Philippe Hernigou1, Arnaud Dubory2, Charles Henri Flouzat Lachaniette2, Issam Khaled2, Nathalie Chevallier2, Helene Rouard2.   

Abstract

PURPOSE: Avascular necrosis of the talus is one of the most notable complications associated with talar neck fractures with frequent evolution of the osteonecrosis into a difficult arthrodesis. We tested whether the injection of bone marrow mesenchymal stem cells (MSCs) could improve the repair process of the osteonecrosis.
MATERIAL AND METHODS: Forty-five early (without collapse) post-traumatic talus osteonecroses (group 1; study group) were treated between 1995 and 2012 with percutaneous injection of progenitor cells (autologous bone marrow concentrate from the iliac crest). The number of MSCs transplanted in each ankle of group 1 was 124 × 103 cells (range 101 × 103 to 164 × 103 cells). The evolution of these osteonecroses treated with autologous bone marrow implantation was compared with the evolution of a control group of 34 talar osteonecroses without collapse and treated with only core decompression (group 2; control group) between 1985 and 1995. The outcome was determined by progression in radiographic stages to collapse, by the need of arthrodesis, and by the time to successfully achieve fusion for patients who needed arthrodesis.
RESULTS: For the 45 ankles with autologous concentrate bone marrow grafting, collapse frequency was lower (27%, 12 among 45 versus 71%, 24 among 34; odds ratio 0.1515, 95% CI 0.0563-0.4079; P = 0.0002) and follow-up showed longer duration of survival before collapse or arthrodesis, compared to 34 ankles of the control patients with core decompression alone. Furthermore, the time to successfully achieve fusion after arthrodesis was significantly shorter in patients treated with bone marrow progenitors as compared with the other ankles, which had core decompression alone.
CONCLUSION: In our study the early conservative surgical treatment with autologous bone marrow grafting improved the natural course of the disease as compared with core decompression alone.

Entities:  

Keywords:  Talus core decompression; Talus fracture; Talus osteonecrosis; Talus stem cell therapy

Mesh:

Year:  2018        PMID: 29305640     DOI: 10.1007/s00264-017-3716-7

Source DB:  PubMed          Journal:  Int Orthop        ISSN: 0341-2695            Impact factor:   3.075


  28 in total

1.  Treatment of osteonecrosis with autologous bone marrow grafting.

Authors:  Philippe Hernigou; Françoise Beaujean
Journal:  Clin Orthop Relat Res       Date:  2002-12       Impact factor: 4.176

2.  Arterial anatomy of the talus: a cadaver and gadolinium-enhanced MRI study.

Authors:  Mark L Prasarn; Anna N Miller; Jonathan P Dyke; David L Helfet; Dean G Lorich
Journal:  Foot Ankle Int       Date:  2010-11       Impact factor: 2.827

3.  Percutaneous autologous bone-marrow grafting for nonunions. Influence of the number and concentration of progenitor cells.

Authors:  Ph Hernigou; A Poignard; F Beaujean; H Rouard
Journal:  J Bone Joint Surg Am       Date:  2005-07       Impact factor: 5.284

Review 4.  Current concepts review: talar fractures.

Authors:  Jamal Ahmad; Steven M Raikin
Journal:  Foot Ankle Int       Date:  2006-06       Impact factor: 2.827

5.  Avascular necrosis of the talus treated by core decompression.

Authors:  M A Mont; L C Schon; M W Hungerford; D S Hungerford
Journal:  J Bone Joint Surg Br       Date:  1996-09

6.  A new form of surgical treatment for patients with avascular necrosis of the talus and secondary osteoarthritis of the ankle.

Authors:  N Kodama; Y Takemura; H Ueba; S Imai; Y Matsusue
Journal:  Bone Joint J       Date:  2015-06       Impact factor: 5.082

7.  Eighty-five talus fractures treated by ORIF with five to eight years of follow-up study of 69 patients.

Authors:  R Szyszkowitz; R Reschauer; W Seggl
Journal:  Clin Orthop Relat Res       Date:  1985-10       Impact factor: 4.176

8.  Vascularized periosteal graft from the first metatarsal bone: a new technique to prevent collapse of osteonecrosis of the talus in children. A case report.

Authors:  Francisco Soldado; Sergi Barrera-Ochoa; Cesar Garcia Fontecha; Sleiman Haddad; David Barastegui; Ignasi Barber; Paulo Rego
Journal:  Microsurgery       Date:  2012-09-13       Impact factor: 2.425

9.  Fractures of the neck of the talus. Long-term evaluation of seventy-one cases.

Authors:  S T Canale; F B Kelly
Journal:  J Bone Joint Surg Am       Date:  1978-03       Impact factor: 5.284

10.  Talar Osteonecrosis Related to Adult Sickle Cell Disease: Natural Evolution from Early to Late Stages.

Authors:  Philippe Hernigou; Charles Henri Flouzat-Lachaniette; Gildasio Daltro; Frederic Galacteros
Journal:  J Bone Joint Surg Am       Date:  2016-07-06       Impact factor: 5.284

View more
  4 in total

1.  Six thousand papers already: "the outcome of a matter is better than its beginning…".

Authors:  Marius M Scarlat; Marko Pećina
Journal:  Int Orthop       Date:  2018-05       Impact factor: 3.075

2.  Ankle osteonecrosis in fifty-one children and adolescent's leukemia survivors: a prospective randomized study on percutaneous mesenchymal stem cells treatment.

Authors:  Philippe Hernigou; Jean Charles Auregan; Arnaud Dubory; Charles Henri Flouzat Lachaniette; Hélène Rouard
Journal:  Int Orthop       Date:  2021-04-23       Impact factor: 3.075

3.  Ankle and foot surgery: from arthrodesis to arthroplasty, three dimensional printing, sensors, artificial intelligence, machine learning technology, digital twins, and cell therapy.

Authors:  Philippe Hernigou; Marius M Scarlat
Journal:  Int Orthop       Date:  2021-09       Impact factor: 3.075

Review 4.  Mesenchymal stromal cell and bone marrow concentrate therapies for musculoskeletal indications: a concise review of current literature.

Authors:  Christian Eder; Katharina Schmidt-Bleek; Sven Geissler; F Andrea Sass; Tazio Maleitzke; Matthias Pumberger; Carsten Perka; Georg N Duda; Tobias Winkler
Journal:  Mol Biol Rep       Date:  2020-05-25       Impact factor: 2.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.